Elanco Animal Health (NYSE:ELAN) Releases FY 2025 Earnings Guidance

Elanco Animal Health (NYSE:ELAN - Get Free Report) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.800-0.860 for the period, compared to the consensus EPS estimate of 0.830. The company issued revenue guidance of $4.5 billion-$4.6 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its Q2 2025 guidance to 0.170-0.210 EPS.

Elanco Animal Health Stock Down 2.1 %

Elanco Animal Health stock traded down $0.26 during midday trading on Friday, reaching $12.02. The stock had a trading volume of 8,518,434 shares, compared to its average volume of 4,981,741. The stock has a market capitalization of $5.97 billion, a P/E ratio of 30.05, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49. The firm's fifty day simple moving average is $9.89 and its 200-day simple moving average is $11.43. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health has a 1-year low of $8.02 and a 1-year high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the firm earned $0.34 earnings per share. The firm's revenue for the quarter was down 1.0% compared to the same quarter last year. As a group, analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ELAN has been the topic of several recent analyst reports. UBS Group lowered their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, February 26th. Stifel Nicolaus boosted their target price on shares of Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday. Morgan Stanley cut their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Barclays decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Piper Sandler cut their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $15.00.

Insider Activity

In other news, Director Lawrence Erik Kurzius purchased 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average cost of $10.20 per share, with a total value of $102,000.00. Following the acquisition, the director now owns 111,459 shares in the company, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.89% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.